Enjoy complimentary customisation on priority with our Enterprise License!
The new drug delivery systems market size is forecast to increase by USD 55.1 billion at a CAGR of 4.5% between 2023 and 2028. The market is experiencing significant growth due to the rising prevalence of chronic diseases among pediatric and geriatric patients. Minimally invasive surgeries and home-care settings are driving the demand for advanced drug delivery systems. However, patent expiry and regulatory hurdles pose challenges to market growth. In the biopharmaceutical market, there is a growing focus on developing drugs for conditions such as kidney diseases, where traditional drug delivery methods have limitations. Furthermore, the development of technologies for delivering poorly soluble drugs is a major trend in the market. Despite these opportunities, the market faces challenges from stringent regulations and the need for extensive clinical trials to ensure safety and efficacy.
The pharmaceutical industry is witnessing a paradigm shift towards advanced drug delivery systems, with auto-injectors and jet-injectors leading the charge. These systems offer convenience, accuracy, and ease of administration, making them increasingly popular for chronic diseases such as cardiovascular diseases, diabetes, cancer, and endocrinology-related conditions. Auto-injectors and jet-injectors have become essential tools in retail and hospital pharmacies, catering to various patient populations, including pediatric and geriatric patients. Starpharma's Dep Drug Delivery and DPX-Danu (Unispray) are notable examples of innovative drug delivery systems that have made a significant impact in the market.
The biopharmaceutical market, driven by patent expiry and regulatory hurdles, is experiencing a demand for new drug delivery systems. Biologics market, particularly in the areas of oncology and metabolism, is expected to benefit significantly from these advancements. The Kidney Cancer Observatory Report highlights the importance of minimally invasive surgeries and innovative drug delivery systems in improving patient outcomes. Qfinity Autoinjector Platform and Insujet devices are some of the latest offerings in this space. The market for new drug delivery systems is poised for growth, with continued investment in R&D and regulatory approvals expected to fuel expansion.
The future looks bright for this sector, as it continues to revolutionize the way therapeutic substances are administered.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The oral drug delivery systems segment is estimated to witness significant growth during the forecast period. The oral route is the most common route for drug administration. Owing to its advantages, including a well-established delivery system that is patient-friendly, convenient, cost-effective, and noninvasive, it has been the most favored drug delivery system in the pharmaceutical industry.
Get a glance at the market share of various segments Request Free Sample
The Oral drug delivery systems segment accounted for USD 90.60 billion in 2018 and showed a gradual increase during the forecast period. However, various physicochemical, biochemical, metabolic, and biological barriers limit the oral drug bioavailability, thereby hampering the growth of the segment. To overcome these hurdles, many technological advances, including nanocarriers, micelles, cyclodextrins, and lipid-based carriers, have been explored to enhance oral drug absorption. Such strategic initiatives are likely to enhance the growth of the segment during the forecast period.
Asia is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
In the realm of biomedicine, the New Drug Delivery Systems (NDDS) market is experiencing significant growth, with North America leading the charge in 2023. This region's dominance can be attributed to the escalating prevalence of chronic diseases, the presence of prominent pharmaceutical and biotech companies, and substantial investments in research and development of novel drugs. In the United States, the surge in major health disorders, largely due to lifestyle modifications and increased consumption of alcohol and tobacco, is driving the demand for advanced drug delivery systems. Meanwhile, in Canada, the rising incidence of breast cancer is fueling the need for more effective drugs, thereby boosting the demand for NDDS.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Rising prevalence of chronic diseases is the key driver of the market. The market is experiencing significant growth due to the increasing prevalence of chronic diseases and the subsequent demand for effective drug-delivery solutions. Chronic conditions such as diabetes, cancer, atherosclerosis, myocardial ischemia, asthma, pulmonary tuberculosis, Parkinson's disease, and Alzheimer's disease require innovative drug delivery systems to enhance therapeutic efficacy. New delivery systems, such as non-long-acting drug delivery systems (NLADDS), are gaining popularity as they enable the targeted delivery of drug molecules into specific tissues through systemic circulation or localized injections. This approach overcomes the limitations of traditional therapies and improves treatment outcomes. As a result, the market for new drug delivery systems is expected to expand substantially in the forecast period, with key players including Auto-injectors, Jet-injectors, and Syringes from the pharmaceutical industry supplying to retail pharmacies and hospital pharmacies worldwide. The World Health Organization (WHO) also the importance of advanced drug delivery systems in addressing the global health burden of chronic diseases.
The rising prevalence of chronic diseases is the upcoming trend in the market. The pharmaceutical industry is witnessing significant advancements in drug delivery systems, particularly in response to the rising prevalence of chronic diseases and the need for efficient drug therapy. Innovative drug delivery technologies, such as auto-injectors and jet-injectors, are gaining popularity due to their precision and ease of use. For instance, nanochannel drug delivery systems (nDS) are a promising technology that enables remote administration of long-term drug delivery. This technology maintains consistent drug levels in the circulatory system, reducing the need for frequent clinical visits and follow-ups with healthcare providers. Additionally, companies like Evox in Oxford, England, are developing DeliverEX drug delivery technology, which targets specific organs, such as the brain and central nervous system. In the US market, Teva Respiratory launched digital inhalers, AirDuo Digihaler and ArmonAir Digihaler, in September 2020. These advancements in drug delivery systems are transforming the pharmaceutical landscape, making treatments more effective and convenient for patients.
Stringent regulations is a key challenge affecting the market growth. New Drug Delivery Systems, including Auto-injectors and Jet-injectors, play a significant role in the Pharmaceutical industry, particularly for managing chronic diseases. Regulatory authorities, such as the World Health Organization, meticulously assess drug data to ensure safety, efficacy, and compatibility with existing pharmacological data, pharmacodynamic effects, and drug interactions. Failure to meet these criteria may result in a Complete Response Letter (CRL) or rejection from regulatory agencies. Applicants receiving a CRL must provide additional data, which could necessitate additional clinical trials and increased Research and Development expenses. In some instances, applicants abandon their applications and terminate drug trials.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Baxter International Inc.: The company offers solutions for drug delivery systems that includes in-class infusion pump and comprehensive portfolio of sets and access devices to administer IV fluids and drugs for patients, under the brand name of Baxter.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The pharmaceutical industry is witnessing a significant shift towards advanced drug delivery systems to address the challenges of chronic diseases, such as diabetes, cancer, and cardiovascular diseases, in retail and hospital pharmacies. Auto-injectors, jet injectors, and syringes are gaining popularity due to their ease of use, improved patient compliance, and reduced risk of needlestick injuries. Biotech and biomedical research have led to innovations like Unispray, Susvimo, and Insujet devices, utilizing nanoparticles, transient permeation enhancers, and dual chamber bags for oral medication administration. The World Health Organization and Formosan Medical Association support these advancements to improve access to the biologics market for various therapeutic substances.
Moreover, government bodies and regulatory hurdles are driving the adoption of self-administration drug delivery devices for the geriatric population and pediatric patients. Topical drug delivery and minimally invasive surgeries are also gaining traction in home-care settings. The biopharmaceutical market is witnessing patent expiry and increasing competition, leading to a focus on developing new drug delivery systems for poorly soluble drugs and addressing bioavailability hurdles. Infectious diseases and allergies are other areas where new drug delivery systems are making a significant impact. Cardiovascular diseases, cancer, and endocrinology are key therapeutic areas benefiting from these advancements. The market is expected to grow in the coming years due to increasing healthcare spending and the need for safer and more effective drug administration methods.
Market Scope |
|
Report Coverage |
Details |
Page number |
144 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.5% |
Market Growth 2024-2028 |
USD 55.1 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
4.24 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
Asia at 41% |
Key countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, Amgen Inc., ANTARES PHARMA INC., AstraZeneca Plc, Baxter International Inc., Becton Dickinson and Co., Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gerresheimer AG, Gilead Sciences Inc., Kindeva Drug Delivery L.P., Medtronic Plc, Merck KGaA, Nemera Group, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., West Pharmaceutical Services Inc., and Ypsomed Holding AG |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.